Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes

Blood

Volumn 87, Issue 2, 1996, Pages 712-716

  Ong, F ^b   Kaiser, U ^b   Seelen, P J ^b   Hermans, J ^b   Wijermans, P W ^b   De Kieviet, W ^b   Jaques, G ^b   Kluin Nelemans, J C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; NERVE CELL ADHESION MOLECULE;

ARTICLE; BLOOD LEVEL; BONE MARROW BIOPSY; BONE RADIOGRAPHY; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PARAPROTEINEMIA; PRIORITY JOURNAL;

EID: 0030034428     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.2.712.bloodjournal872712     Document Type: Article

References (19)

1. Ong F, Hermans J, Noordijk EM, Kluin-Nelemans JC: Is the Dune and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice?: Application of three classification systems on a large population based registry on paraproteinemia and multiple myeloma. Ann Hematol 70:19, 1995
2. Salmon SE, Cassady JR: Plasma cell neoplasms, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, p 1853
3. Kyle RA: Plasma cell proliferative disorders, in Hoffmann R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds): Hematology. Basic Principles and Practice (ed 2). New York, NY, Churchil Livinsgstone, 1995, p 1354
4. Duggan DB, Schattner A: Unusual manifestations of mono-clonal gammopathies: Autoimmune and idiopathic syndromes. Am J Med 81:864, 1986
5. Kyle RA, Lust J A: Monoclonal gammopathies of undetermined significance Semin Hematol 26:176, 1989
6. Van Camp B, Durie BGM, Spier C, de Waele M, van Riet I, Vela E, Frutiger Y, Richter L, Grogan TM: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKHI; Leu19). Blood 76:377, 1990
7. Barker HF, Hamilton MS, Ball J, Drew M, Franklin IM: Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant plasma cells. Br J Haematol 81:331, 1992
8. Kaiser U, Auerbach B, Oldenburg M: The neural cell adhesion molecule NCAM in multiple myeloma. Leukemia Lymphoma 18:179, 1995
9. Kaiser U, Jaques G, Havemann K, Auerbach B: Serum NCAM. A potential new prognostic marker for multiple myeloma. Blood 83:871,1994 (letter)
10. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A: C-reactive protein and β2-microglobulin produce a simple and powerful myeloma staging system. Blood 79:733, 1992
11. Lymphoma Tumor Group: Plasma cell disorders, in Osoba D (ed): Cancer Treatment Policies. Vancouver, British Columbia. Canada, British Columbia Cancer Agency, 1992, p 4
12. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:842, 1975
13. Cavo M, Galieni P, Zuffa E, Baccarani M, Gobbi M, Tura S: Prognostic variables and clinical staging in multiple myeloma Blood 74:1774, 1989
14. Simonsson B, Brennig G. Källander C, Åhre A: Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma Eur J Clin Invest 17:336, 1987
15. Rayener HC, Haynes AP, Thompson JR, Russell N, Retcher J: Perspectives in multiple myeloma: Survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Quart J Med 209:517, 1991
16. Greipp PR: Monoclonal gammopathies: New approaches to clinical problems in diagnosis and prognosis. Blood Rev 3:222, 1989
17. Auerbach B, Jaques G, Bosslet K, Havemann K, Madry N: The neural cell adhesion molecule: A new serum tumor marker in small cell lung cancer, in Klapdor R (ed): Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties. München, Germany, W. Zuckschwerdt Verlag, 1992, p 130
18. Greco C, Ameglio F, Alvino S, Cianciulli AM, Giovannelli M, Mattei F, Vitelli G, Venture I, Lopez M, Gandolfo GM: Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers. Acta Haematol 92:1, 1994
19. Du Villard L, Guiguet M, Casasnovas R-O, Caillot D, Monnier-Zeller V, Bernard A, Guy H, Solary E: Diagnostic value of serum IL-6 level in monoclonal gammopathies. Br J Haematol 89:243, 1995